Working… Menu

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02514447
Recruitment Status : Active, not recruiting
First Posted : August 3, 2015
Last Update Posted : August 27, 2019
Information provided by (Responsible Party):
G1 Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : September 28, 2018
Estimated Study Completion Date : January 2020
Certification/Extension First Submitted : July 23, 2019